| Targeting MCL-1 protein to treat cancer: opportunities and challenges SI Tantawy, N Timofeeva, A Sarkar, V Gandhi Frontiers in oncology 13, 1226289, 2023 | 29 | 2023 |
| Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the … JR Brown, SP Desikan, B Nguyen, H Won, SI Tantawy, S McNeely, ... Blood 142, 326, 2023 | 12 | 2023 |
| Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies SI Tantawy, A Sarkar, S Hubner, Z Tan, WG Wierda, A Eldeib, S Zhang, ... Clinical Cancer Research 29 (2), 446-457, 2023 | 9 | 2023 |
| S146: Genomic Evolution and Resistance to Pirtobrutinib in covalent Btk-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia (Cll) Patients: Results From The Phase I/Ii … JR Brown, SP Desikan, B Nguyen, H Won, S Tantawy, SC Mcneely, ... HemaSphere 7, e6233246, 2023 | 3 | 2023 |
| Pharmacological profiling of cells from patients with chronic lymphocytic leukemia (CLL) treated with pirtobrutinib SI Tantawy, B Aslan, LS Chen, L Iles, PA Thompson, N Jain, WG Wierda, ... Blood 140 (Supplement 1), 501-502, 2022 | 2 | 2022 |
| GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY. K Patel, JR Brown, SP Desikan, B Nguyen, H Won, SI Tantawy, ... Hematological Oncology 41, 2023 | 1 | 2023 |
| Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability SI Tantawy, N Timofeeva, A Hernandez, A Sarkar, V Gandhi Oncotarget 14, 653, 2023 | 1 | 2023 |
| Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers N Timofeeva, B Herrera, SI Tantawy, H Fujiwara, L Loza, M Hatakeyama, ... Blood 144, 1850, 2024 | | 2024 |
| Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib B Aslan, G Manyam, LR Iles, SI Tantawy, SP Desikan, WG Wierda, ... Blood Advances 8 (17), 4487-4501, 2024 | | 2024 |
| Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia SI Tantawy, N Timofeeva, H Fujiwara, M Hatakeyama, B Herrera, L Loza, ... Blood 142, 1453, 2023 | | 2023 |
| Effects of AS-1763 in Combination with other Targeted Agents for Chronic Lymphocytic Leukemia L Loza, N Timofeeva, S Tantawy, V Gandhi | | 2023 |
| Curing CLL: one clone at a time B Aslan, SI Tantawy, V Gandhi Blood Advances 7 (9), 1926, 2022 | | 2022 |
| Phosphatidylserine and the thrombin–antithrombin complex as markers for hypercoagulability in Egyptian beta-thalassemia patients MM Sadek, AS Ahmed, SM El Fiky, SI Tantawy, AM Hassan The Egyptian Journal of Haematology 47 (3), 210-216, 2022 | | 2022 |
| APR-246 induces ferroptosis and overcomes cisplatin resistance in ovarian cancer A Hernandez, C Mai, S Tantawy, M Ayres, Z Siddik, V Gandhi | | 2022 |
| Mechanism of APR-246 and Sensitization of Cells to Targeted Agents AV Drawdy, S Tantawy, V Gandhi The University of Texas MD Anderson Cancer Center, 2021 | | 2021 |
